Page 5 - Pediatric Disease News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesHong kongQian jiangJianyong liJianxiang wangPrnewswire ascentage pharmaHuafeng wangElias jabbourXiaojun huangJie jinKeshu zhouSikander ailawadhiXiaoyuan gongYifan zhaiLiposome mitoxantrone

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesUnited kingdomQian jiangHong kongHagop kantarjianJianyong liPrnewswire ascentage pharmaYifan zhaiJianxiang wangAscentage pharmaLiposome mitoxantroneInnovent biologicsSikander ailawadhiHuafeng wangHongsheng zhou

Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and.

Western australiaHong kongYifan zhaiPrnewswire ascentage pharmaAscentage pharmaMajor nationalNational reimbursement drug listChina national medical products administrationEuropean society of medical oncologyDana farber cancer instituteMd anderson cancer centerMini oralMedical oncologyChief medical officerMadrid timeBeijing time

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

SYDNEY, Oct. 23, 2023 /PRNewswire/ Kazia Therapeutics Limited , an oncology-focused drug development company, announces that selected clinical data from the company s ongoing Phase 1 clinical.

New south walesUnited statesCarlosa gomez rocaJohn friendKazia therapeuticsDrug administrationEuropean society of medical oncology congressKazia therapeutics limitedExchange commissionEuropean societyMedical oncology congressToulouse franceChief executive officerTherapeutics limitedOrphan drugFast track designation

First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongYang shenYifan zhaiInnovent biologicsElias jabbourAscentage pharmaPrnewswire ascentage pharmaSuning chenWeili zhaoMd anderson cancer centerShanghai institute of hematologyFirst affiliated hospital of soochow universityDana farber cancer instituteChina national medical products administrationNational reimbursement drug list